首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis and serotonergic activity of 3-(2-(pyrrolidin-1-yl)ethyl)indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
【24h】

Synthesis and serotonergic activity of 3-(2-(pyrrolidin-1-yl)ethyl)indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.

机译:3-(2-(吡咯烷-1-基)乙基)吲哚的合成及其血清素能活性:对h5-HT1D受体的强效激动剂,对h5-HT1B受体的选择性高。

获取原文
获取原文并翻译 | 示例
           

摘要

The design, synthesis, and biological evaluation of a novel series of 3-[2-(pyrrolidin-1-yl)ethyl]indoles with excellent selectivity for h5-HT1D (formerly 5-HT1Dalpha) receptors over h5-HT1B (formerly 5-HT1Dbeta) receptors are described. Clinically effective antimigraine drugs such as Sumatriptan show little selectivity between h5-HT1D and h5-HT1B receptors. The differential expression of h5-HT1D and h5-HT1B receptors in neural and vascular tissue prompted an investigation of whether a compound selective for the h5-HT1D subtype would have the same clinical efficacy but with reduced side effects. The pyrrolidine 3b was initially identified as having 9-fold selectivity for h5-HT1D over h5-HT1B receptors. Substitution of the pyrrolidine ring of 3b with methylbenzylamine groups gave compounds with nanomolar affinity for the h5-HT1D receptor and 100-fold selectivity with respect to h5-HT1B receptors. Modification of the indole 5-substituent led to the oxazolidinones 24a,b with up to 163-fold selectivity for the h5-HT1D subtype and improved selectivity over other serotonin receptors. The compounds were shown to be full agonists by measurement of agonist-induced [35S]GTPgammaS binding in CHO cells expressed with h5-HT receptors. This study suggests that the h5-HT1D and h5-HT1B receptors can be differentiated by appropriate substitution of the ligand in the region which binds to the aspartate residue and reveals a large binding pocket in the h5-HT1D receptor domain which is absent for the h5-HT1B receptor. The compounds described herein will be important tools to delineate the role of h5-HT1D receptors in migraine.
机译:设计,合成,和生物学评估的新型3- [2-(吡咯烷-1-基)乙基]吲哚与h5-HT1B(以前为5-)对h5-HT1D(以前为5-HT1Dalpha)受体具有优异的选择性描述了HT1Dbeta)受体。临床上有效的抗偏头痛药物,例如舒马曲坦,对h5-HT1D和h5-HT1B受体之间的选择性很小。 h5-HT1D和h5-HT1B受体在神经和血管组织中的差异表达促使人们开始研究选择性针对h5-HT1D亚型的化合物是否具有相同的临床疗效,但副作用减少。最初确定吡咯烷3b对h5-HT1D的选择性是h5-HT1B受体的9倍。用甲基苄胺基团取代3b的吡咯烷环,得到对h5-HT1D受体具有纳摩尔摩尔亲和力的化合物,相对于h5-HT1B受体具有100倍的选择性。吲哚5-取代基的修饰导致恶唑烷酮24a,b对h5-HT1D亚型具有高达163倍的选择性,并且与其他5-羟色胺受体相比具有更高的选择性。通过测量激动剂诱导的由h5-HT受体表达的CHO细胞中[35S] GTPgammaS的结合,表明该化合物是完全激动剂。这项研究表明,h5-HT1D和h5-HT1B受体可以通过在与天门冬氨酸残基结合的区域中适当配体的替换来区分,并揭示h5-HT1D受体域中没有h5的大结合口袋-HT1B受体。本文所述的化合物将是描述偏头痛中h5-HT1D受体作用的重要工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号